ReviewCancer metastasis reviews2026
Thymic epithelial tumors: what's next?
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic epithelial tumors (TETs) are rare malignancies arising in an organ central to T cell development and immune tolerance, creating a distinctive interface between tumor biology and immunotherapy. Complete surgical resection remains the mainstay for resectable disease, whereas systemic treatment options for unresectable, recurrent, and metastatic TETs remain limited. The unique immunobiology of thymoma, particularly impaired central immune tolerance, may account for the unusual balance between antitumor activity and severe immune-related adverse events observed with immune checkpoint blockade. Recent molecular and immune profiling has begun to reveal biologically distinct TET subtypes and potential therapeutic vulnerabilities, including alterations in cell-cycle, PI3K/AKT/mTOR, RTK/RAS/MAPK, and DNA damage-response pathways, as well as epigenetic and immune regulatory mechanisms. Emerging strategies, including antibody-drug conjugates and biomarker-informed targeted and immune therapies, may expand systemic treatment options for advanced disease. This review examines these developments in the context of the distinctive biology of the thymus and highlights the key unanswered questions that may shape the next generation of TET research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.